{"id":1018619,"date":"2026-11-09T07:24:16","date_gmt":"2026-11-09T12:24:16","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-reports-third-quarter-2026-financial-results-and-recent-business-highlights\/"},"modified":"2026-11-09T07:24:16","modified_gmt":"2026-11-09T12:24:16","slug":"aura-biosciences-reports-third-quarter-2026-financial-results-and-recent-business-highlights","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/aura-biosciences-reports-third-quarter-2026-financial-results-and-recent-business-highlights\/","title":{"rendered":"Aura Biosciences Reports Third Quarter 2026 Financial Results and Recent Business Highlights"},"content":{"rendered":"
\n

\n Phase 3 CoMpass trial on track for topline data in 2H 2027; all participants have completed treatment visits<\/em>\n <\/p>\n

\n Established relationship with industry-leading CDMO providing designated manufacturing capacity for bel-sar<\/em>\n <\/p>\n

\n Early choroidal melanoma investor and analyst virtual event planned for December 8, 2026<\/em>\n <\/p>\n

\n Expected cash runway into 1H 2029<\/em>\n <\/p>\n

BOSTON, Nov. 09, 2026 (GLOBE NEWSWIRE) — Aura Biosciences, Inc.<\/u><\/a> (NASDAQ: AURA) (\u201cAura\u201d or the \u201cCompany\u201d) a clinical-stage biotechnology company developing a potentially transformative first-in-class therapy for patients with ocular cancers, today reported financial results for the third quarter ended September 30, 2026, and provided a business update.<\/p>\n

\u201cDuring the third quarter, we continued to execute against our focused ocular oncology strategy and build the operational capabilities needed for our next stage of development,\u201d said Natalie Holles, Chief Executive Officer of Aura Biosciences. \u201cWith all treatment visits completed in the CoMpass trial, our team is focused on ensuring excellence in all elements of the bel-sar program as we advance toward topline pivotal data in the second half of next year and position bel-sar as the first potential vision-preserving front-line therapy for early choroidal melanoma.\u201d<\/p>\n

\n
\n Recent Business Highlights<\/u>
\n <\/strong>\n <\/p>\n

\n Phase 3 CoMpass Trial in Early Choroidal Melanoma<\/strong>\n <\/p>\n

Enrollment is complete with 108 participants in the Phase 3 CoMpass trial of belzupacap sarotalocan (bel-sar) for the treatment of early choroidal melanoma, the most common primary tumor of the eye which carries an approximately 50% risk of advancing to metastatic disease. As of the third quarter of 2026, all participants have completed their treatment regimen and are in the 24-month follow-up observation period. The trial is on track to deliver topline data from the 15-month primary endpoint in the second half of 2027.<\/p>\n

The trial is being conducted under a Special Protocol Assessment (SPA) agreement with the U.S. Food and Drug Administration (FDA). The SPA represents alignment with the FDA on the trial design and planned analyses to support a potential Biologics License Application (BLA) of bel-sar. If successful, bel-sar would be the first approved front-line vision-preserving therapy for patients with early choroidal melanoma, providing a meaningful new treatment option where no FDA-approved drug therapies currently exist.<\/p>\n

\n
\n Additional Ocular Oncology Programs<\/em>
\n <\/strong>\n <\/p>\n

Aura continues to advance the development of bel-sar in metastases to the choroid and cancers of the ocular surface in ongoing early clinical trials. In the first quarter of 2027, Aura expects to provide an update on both programs, including details on disease burden, trial design, and timelines to future data read-outs from these studies.<\/p>\n

\n
\n Operational Updates<\/u>
\n <\/strong>\n <\/p>\n

During the quarter, Aura established a new supply relationship with an industry-leading contract development and manufacturing organization (CDMO) with extensive commercial experience in the manufacture of viral vector-based medicinal products. In a key element of the relationship, Aura and its CDMO partner are establishing manufacturing capacity which will be designated for bel-sar development and commercial supply production.<\/p>\n

\u201cWe are very pleased to enter this new CDMO relationship, which we believe positions bel-sar for regulatory and commercial success as we advance toward topline data and completion of the CoMpass study,\u201d said Susan Abu-Absi, Ph.D., Chief Operating Officer of Aura Biosciences. \u201cDesignated capacity is intended to provide us with long-term control over our production scheduling, and we look forward to working with our new partner to advance this important element of the bel-sar program.\u201d<\/p>\n

\n
\n Upcoming Events<\/u>
\n <\/strong>\n <\/p>\n

Aura will host an early choroidal melanoma investor and analyst virtual event on Tuesday, December 8, 2026, from 7:30-9:00 a.m. ET. Members of Aura\u2019s management team will be joined by key opinion leader, Dr. Arun Singh, Director of the Department of Ophthalmic Oncology in the Cole Eye Institute of the Cleveland Clinic. The event will address the current treatment paradigm and unmet need, and an updated analysis of the epidemiology of early choroidal melanoma. To register for the virtual event, click here<\/a>.<\/p>\n

Aura also announced that Natalie Holles, Chief Executive Officer and President, will participate in the following upcoming investor conferences in the fourth quarter of 2026:<\/p>\n